Evidence map›Paper›PMID 35275285›Full record

ArticleBreast cancer research and treatment2022

Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.

Erin J Aiello Bowles, Cody Ramin, Diana S M Buist, Heather Spencer Feigelson, Sheila Weinmann, Lene H S Veiga, Clara Bodelon, Rochelle E Curtis, Jacqueline B Vo, Amy Berrington de Gonzalez and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Radiotherapy, chemotherapy, and heart disease.Breast cancer research and treatment · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Erin J Aiello BowlesKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, 1730 Minor Ave, Suite 1600, Seattle, WA, 98101, USA. Erin.a.bowles@kp.org.ORCID http://orcid.org/0000-0001-6287-7391
Cody RaminDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Diana S M BuistKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, 1730 Minor Ave, Suite 1600, Seattle, WA, 98101, USA.
Heather Spencer FeigelsonBernard J. Tyson Kaiser Permanente School of Medicine, Pasadena, CA, USA.
Sheila WeinmannCenter for Health Research, Kaiser Permanente Northwest, Portland, OR, USA.
Lene H S VeigaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Clara BodelonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Rochelle E CurtisDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Jacqueline B VoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Amy Berrington de GonzalezDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Gretchen L GierachDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
National Cancer Institute · USKaiser Permanente · USKaiser Permanente Center for Health Research · USKaiser Permanente Washington Health Research Institute · US

Funding

Studies of Populations Exposed to Therapeutic Medical Radiation and Other AgentsZIACP010131 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MORTON, LINDSAY · 2009 to 2025
$81.0M
Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Diana L Miglioretti · 2011 to 2026
$52.9M
Commonly Used Medications and Breast Cancer RecurrenceR01CA120562 · NCI · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI BOUDREAU, DENISE M · 2007 to 2011
$2.1M
Group Health Cancer Research Program Research Specialist AwardR50CA211115 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BOWLES, ERIN JANELLE AIELLO · 2017 to 2021
$919k
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01CN067009 · CN · FRED HUTCHINSON CANCER RESEARCH CENTER · PI THOMAS, DAVID B · 1996 to 1997
–
NCI NIH HHS HHSN 261201700564PNCI NIH HHS HHSN 5N91020P00327NCI NIH HHS HHSN75N91019P00076NCI NIH HHS N01 CN067009NCI NIH HHS N01-CN-67009NCI NIH HHS N01 PC035142NCI NIH HHS N01-PC-35142NCI NIH HHS P01 CA154292NCI NIH HHS R01 CA120562NCI NIH HHS R50 CA211115NIH HHS 1R01CA120562NIH HHS P01CA154292NIH HHS R50CA211115
6 · The paper itself

Abstract

purposeThis retrospective cohort study examined patterns of endocrine therapy initiation over time and by demographic, tumor, and treatment characteristics.

methodsWe included 7777 women from three U.S. integrated healthcare systems diagnosed with incident stage I-III hormone receptor-positive breast cancer between 2001 and 2016. We extracted endocrine therapy from pharmacy dispensings, defining initiation as dispensings within 12 months of diagnosis. Demographic, tumor, and treatment characteristics were collected from electronic health records. Using generalized linear models with a log link and Poisson distribution, we estimated initiation of any endocrine therapy, tamoxifen, and aromatase inhibitors (AI) over time with relative risks (RR) and 95% confidence intervals (CI) adjusted for age, tumor characteristics, diagnosis year, other treatment, and study site.

resultsAmong women aged 20+ (mean 62 years), 6329 (81.4%) initiated any endocrine therapy, and 1448 (18.6%) did not initiate endocrine therapy. Tamoxifen initiation declined from 67 to 15% between 2001 and 2016. AI initiation increased from 6 to 69% between 2001 and 2016 in women aged ≥ 55 years. The proportion of women who did not initiate endocrine therapy decreased from 19 to 12% between 2002 and 2014 then increased to 17% by 2016. After adjustment, women least likely to initiate endocrine therapy were older (RR = 0.81, 95% CI 0.77-0.85 for age 75+ vs. 55-64), Black (RR = 0.93, 95% CI 0.87-1.00 vs. white), and had stage I disease (RR = 0.88, 95% CI 0.85-0.91 vs. stage III).

conclusionsDespite an increase in AI use over time, at least one in six eligible women did not initiate endocrine therapy, highlighting opportunities for improving endocrine therapy uptake in breast cancer survivors.

Indexed as

Breast NeoplasmsAntineoplastic Agents, HormonalAromatase InhibitorsFemaleHumansRetrospective StudiesTamoxifenAntineoplastic Agents, HormonalAromatase InhibitorsTamoxifenBreast cancerEndocrine therapyInitiationTrend

Identifiers

PMID35275285
PMCPMC10135399
OpenAlexW4221126835

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.